Arkin Bio-Ventures II

View All

pharma news
Ofev’s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment

Boehringer Ingelheim’s Ofev (nintedanib) has received FDA recommendation for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype Interstitial Lung Disease - ILD – a group of a large number of lung disorders resulting in scarring or fibrosis of lungs, caused by conditi...

Find More